InCephalo AG Announces Appointment of Lauren E. Abrey, MD as Chief Medical Officer

Allschwil, Switzerland, June 30th 2022

InCephalo AG announces that Lauren E. Abrey, MD will join the company as Chief Medical Officer (CMO). Dr. Abrey will lead the clinical and medical programs of INCEPHALO in support of the company’s lead asset, InC01, a novel IL-12 drug. She will help further advance INCEPHALO’s platform, addressing the unmet medical need for novel therapies for brain cancer.

«We are delighted to have Lauren join INCEPHALO’s executive management team in this exciting phase for the company. With her vast experience in the field of brain cancer, either as a physician treating patients, as a Vice-Chair of the Neurology Department at Memorial Sloan Kettering Cancer Center or during her roles at Roche and Novartis, she will add tremendous value to our drug development programs» says Dr Carlo Bertozzi, CEO and co-founder of INCEPHALO.

Lauren Abrey is a recognised international expert in the field of neuro-oncology; she had an active clinical practice and led numerous clinical trials for more than a decade prior to moving to the life sciences industry. Before joining INCEPHALO, she held various roles in the pharmaceutical industry, focusing on brain cancers and other solid tumours. She is an active member of the neuro-oncology societies in Switzerland, Europe and the US. She joins INCEPHALO from Novartis, where she was Vice-President & Head of the Global Medical Affairs Franchise for Solid Tumors and Rare Diseases.

«I am truly delighted to join INCEPHALO at this pivotal phase of the company’s development. I am looking forward to bringing together my deep passion for neuro-oncology with my more recent experience in the pharmaceutical industry. The lack of progress in new brain tumor treatments highlights the relevance of novel approaches and I am convinced that InC01 and the platform being developed by INCEPHALO has high potential to advance treatment options for brain tumor patients.» says Dr. Lauren Abrey.

About INCEPHALO

InCephalo AG is a Switzerland-based preclinical biotechnology company founded in 2021 by leading experts in the field of brain cancer. The company leverages its proprietary technology platform to develop compartment-locked (C-Locked) therapies that are tailor-made for local applications for brain cancer. INCEPHALO’s platform aims to deliver therapies to offer better response rates, more prolonged survival and improved quality of life to patients with brain cancer.

To learn more, visit www.InCephalo.com.

For further details, please contact:

Dr Carlo Bertozzi, CEO and co-founder bertozzi@InCephalo.com